Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Intermittent Treatment Interruption and Its Effect on Multidrug Resistant Tuberculosis Treatment Outcome in Ethiopia Publisher Pubmed



Tola HH1, 2 ; Holakouienaieni K1 ; Mansournia MA1 ; Yaseri M1 ; Tesfaye E2 ; Mahamed Z2 ; Sisay MM3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Tehran University of Medical Sciences, School of Public Health, Department of Epidemiology and Biostatistics, Tehran, Iran
  2. 2. Ethiopian Public Health Institute, Tuberculosis/HIV Research Directorate, Addis Ababa, Ethiopia
  3. 3. Saint Peter’s Specialized Hospital, Research and Evidence Generation Directorate, Addis Ababa, Ethiopia

Source: Scientific Reports Published:2019


Abstract

Treatment interruption is one of the main risk factors of poor treatment outcome and occurrence of additional drug resistant tuberculosis. This study is a national retrospective cohort study with 10 years follow up period in MDR-TB patients in Ethiopia. We included 204 patients who had missed the treatment at least for one day over the course of the treatment (exposed group) and 203 patients who had never interrupted the treatment (unexposed group). We categorized treatment outcome into successful (cured or completed) and unsuccessful (lost to follow up, failed or died). We described treatment interruption by the length of time between interruptions, time to first interruption, total number of interruption episodes and percent of missed doses. We used Poisson regression model with robust standard error to determine the association between treatment interruption and outcome. 82% of the patients interrupted the treatment in the first six month of treatment period, and considerable proportion of patients demonstrated long intervals between two consecutive interruptions. Treatment interruption was significantly associated with unsuccessful treatment outcome (Adjusted Risk Ratio (ARR) = 1.9; 95% CI (1.4–2.6)). Early identification of patients at high risk of interruption is vital in improving successful treatment outcome. © 2019, The Author(s).